ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -714 Thousand EUR | -2063.64% |
| 2022 | -33 Thousand EUR | 98.89% |
| 2021 | -2.97 Million EUR | 67.39% |
| 2020 | -9.13 Million EUR | -27.73% |
| 2019 | -7.14 Million EUR | -20.05% |
| 2018 | -5.95 Million EUR | 40.75% |
| 2017 | -10.04 Million EUR | 43.92% |
| 2016 | -17.92 Million EUR | 51.38% |
| 2015 | -36.85 Million EUR | -1192.77% |
| 2014 | -2.85 Million EUR | 59.81% |
| 2013 | -7.09 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.6 Million EUR | 0.0% |
| 2023 Q1 | 2.02 Million EUR | 6242.42% |
| 2023 Q3 | -1.02 Million EUR | -143.91% |
| 2023 Q4 | -714 Thousand EUR | 30.21% |
| 2023 FY | -714 Thousand EUR | -2063.64% |
| 2023 Q2 | 2.33 Million EUR | 14.95% |
| 2022 Q2 | 465 Thousand EUR | 604.53% |
| 2022 Q3 | -412 Thousand EUR | -188.6% |
| 2022 FY | -33 Thousand EUR | 98.89% |
| 2022 Q1 | 66 Thousand EUR | 102.22% |
| 2022 Q4 | -33 Thousand EUR | 91.99% |
| 2021 Q4 | -2.97 Million EUR | 11.87% |
| 2021 FY | -2.97 Million EUR | 67.39% |
| 2021 Q3 | -3.37 Million EUR | 27.6% |
| 2021 Q2 | -4.66 Million EUR | 1.17% |
| 2021 Q1 | -4.72 Million EUR | 48.29% |
| 2020 Q1 | -7.71 Million EUR | -7.88% |
| 2020 Q3 | -9.15 Million EUR | -19.55% |
| 2020 Q4 | -9.13 Million EUR | 0.26% |
| 2020 Q2 | -7.65 Million EUR | 0.7% |
| 2020 FY | -9.13 Million EUR | -27.73% |
| 2019 Q4 | -7.14 Million EUR | 0.83% |
| 2019 Q3 | -7.2 Million EUR | 13.88% |
| 2019 Q2 | -8.37 Million EUR | 0.69% |
| 2019 Q1 | -8.42 Million EUR | -41.55% |
| 2019 FY | -7.14 Million EUR | -20.05% |
| 2018 FY | -5.95 Million EUR | 40.75% |
| 2018 Q4 | -5.95 Million EUR | 0.0% |
| 2018 Q3 | -5.95 Million EUR | 15.19% |
| 2018 Q2 | -7.02 Million EUR | -2.93% |
| 2018 Q1 | -6.82 Million EUR | 32.13% |
| 2017 Q3 | -10.04 Million EUR | 32.46% |
| 2017 Q2 | -14.87 Million EUR | -1.36% |
| 2017 Q1 | -14.67 Million EUR | 18.09% |
| 2017 FY | -10.04 Million EUR | 43.92% |
| 2017 Q4 | -10.04 Million EUR | -0.0% |
| 2016 Q2 | -26.78 Million EUR | -1.9% |
| 2016 FY | -17.92 Million EUR | 51.38% |
| 2016 Q1 | -26.28 Million EUR | 28.68% |
| 2016 Q3 | -17.62 Million EUR | 34.22% |
| 2016 Q4 | -17.92 Million EUR | -1.7% |
| 2015 Q3 | -36.85 Million EUR | 18.23% |
| 2015 Q1 | -50.66 Million EUR | -1676.92% |
| 2015 Q4 | -36.85 Million EUR | 0.0% |
| 2015 FY | -36.85 Million EUR | -1192.77% |
| 2015 Q2 | -45.07 Million EUR | 11.03% |
| 2014 FY | -2.85 Million EUR | 59.81% |
| 2014 Q3 | -2.85 Million EUR | 0.0% |
| 2014 Q4 | -2.85 Million EUR | 0.0% |
| 2014 Q1 | 11.14 Million EUR | 0.0% |
| 2013 FY | -7.09 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIVAX Société Anonyme | -196.47 Million EUR | 99.637% |
| Adocia SA | 127 Thousand EUR | 662.205% |
| Aelis Farma SA | -16.19 Million EUR | 95.59% |
| Biophytis S.A. | 2.7 Million EUR | 126.415% |
| Advicenne S.A. | 12.17 Million EUR | 105.864% |
| genOway Société anonyme | 2.97 Million EUR | 124.016% |
| IntegraGen SA | -709.74 Thousand EUR | -0.599% |
| Medesis Pharma S.A. | 1.15 Million EUR | 161.647% |
| Neovacs S.A. | -237.08 Thousand EUR | -201.155% |
| NFL Biosciences SA | -2.27 Million EUR | 68.627% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 116.389% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 14.033% |
| Sensorion SA | 1.37 Million EUR | 151.806% |
| Theranexus Société Anonyme | 2.44 Million EUR | 129.213% |
| TME Pharma N.V. | -1.07 Million EUR | 33.828% |
| Valbiotis SA | -18.13 Million EUR | 96.064% |
| TheraVet SA | 12.78 Thousand EUR | 5684.67% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 132.752% |
| argenx SE | -1.83 Billion EUR | 99.961% |
| BioSenic S.A. | 28.04 Million EUR | 102.546% |
| Celyad Oncology SA | -6.1 Million EUR | 88.299% |
| DBV Technologies S.A. | -114.95 Million USD | 99.379% |
| Galapagos NV | -157.2 Million EUR | 99.546% |
| Genfit S.A. | -7.61 Million EUR | 90.619% |
| GeNeuro SA | 5.91 Million EUR | 112.08% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 97.157% |
| Innate Pharma S.A. | -30.71 Million EUR | 97.675% |
| Inventiva S.A. | 10.48 Million EUR | 106.807% |
| MaaT Pharma SA | -10.2 Million EUR | 93.003% |
| MedinCell S.A. | 39.5 Million EUR | 101.808% |
| Nanobiotix S.A. | -24.71 Million EUR | 97.111% |
| Onward Medical N.V. | -12.89 Million EUR | 94.463% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 149.918% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 102.632% |
| Oxurion NV | 10.71 Million EUR | 106.667% |
| Pharming Group N.V. | 99.4 Million EUR | 100.718% |
| Poxel S.A. | 44.55 Million EUR | 101.602% |
| GenSight Biologics S.A. | 16.29 Million EUR | 104.382% |
| Transgene SA | -14.4 Million EUR | 95.045% |
| Financière de Tubize SA | 78.62 Million EUR | 100.908% |
| UCB SA | 2.17 Billion EUR | 100.033% |
| Valneva SE | 82.73 Million EUR | 100.863% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 96.146% |